Morgan Stanley Hikes Labcorp (LH) Holdings Price Target to $283 Affirms ‘Overweight’ Rating

Laboratory Corporation of America Holdings (NYSE:LH) is one of the best healthcare stocks to buy now. On June 11, Morgan Stanley reiterated the stock’s ‘Overweight’ rating and raised the 12-month price target to $283 from $270.

Morgan Stanley Hikes Labcorp (LH) Holdings Price Target to $283 Affirms ‘Overweight’ Rating

A scientist performing a blood test on a patient using life sciences tools & services.

The adjustment underscores the investment firm’s confidence in the company’s growth prospects as it also faces durable demand for its products. LabCorp has already unveiled new product launches, including LabCorp Plasma Complete. It’s also working on genetic risk label tests as part of its strategic focus on high-growth areas.

Laboratory Corporation of America Holdings (NYSE:LH) is a global life sciences and healthcare company. It provides laboratory services for diagnosis, healthcare decisions, and drug development. Its services include clinical lab tests, drug development support, and testing for various conditions, including oncology, genetics, and infectious diseases.

While we acknowledge the potential of LH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Stocks Analysts Are Upgrading Today and 13 Best AI Stocks to Buy Under $10.

Disclosure: None.